{"product_id":"hisunpharm-business-model-canvas","title":"Hisun Pharmaceutical Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma Business Model Canvas: R\u0026amp;D, Manufacturing, Distribution \u0026amp; Revenue Snapshot\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore Hisun Pharmaceutical’s Business Model Canvas to uncover how it creates value across R\u0026amp;D, manufacturing, and distribution while monetizing branded and generics portfolios. This concise, actionable snapshot highlights key partners, cost drivers, and revenue streams for investors and strategists. Purchase the full Word\/Excel canvas for a section-by-section blueprint you can use for benchmarking and planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborate closely with four key regulators—NMPA, US FDA, EMA and WHO Prequalification—to secure market access and ongoing compliance. Joint inspections and regulator guidance accelerate approvals and lower remediation risk. Transparent engagement de-risks filings and sustains export eligibility; WHO Prequalification has operated since 2001, underpinning global procurement standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic \u0026amp; hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartner with universities and clinical hospitals for discovery, translational research, and investigator-led trials, leveraging clinician access to accelerate indication expansion and real-world evidence generation; in 2024 investigator-initiated studies comprised roughly 35–45% of non-industry clinical trials in major markets. Shared labs and competitive grants reduce early-stage R\u0026amp;D capital intensity, often covering 30–60% of initial project costs, lowering burn and speeding go\/no-go decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCo-develop biologics and specialty drugs with biotech innovators to fill pipeline gaps, tapping a global biologics market estimated at USD 390 billion in 2024. Risk-sharing agreements spread development costs and timelines, reducing upfront capex and aligning milestones. Option and licensing structures unlock global reach by enabling staged rights transfers, regional partners, and royalty streams to scale commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs \u0026amp; CMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHisun uses CROs for preclinical, clinical and pharmacovigilance to scale efficiently; the global CRO market was about 56 billion USD in 2024, accelerating trials and risk sharing. CMOs supply surge capacity and specialized dosage forms; the CMO market was near 62 billion USD in 2024, enabling flexible manufacturing to improve time-to-market and control costs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse CROs: preclinical, clinical, PV\u003c\/li\u003e\n\u003cli\u003eUse CMOs: surge capacity, specialty forms\u003c\/li\u003e\n\u003cli\u003eBenefits: faster TTM, lower capex and variable costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors \u0026amp; tender partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHisun formed alliances with 35+ international distributors and 12 local tender agents in 2024, expanding hospital coverage to about 1,200 facilities; partners navigate reimbursement, tenders, and hospital listings to accelerate market access. Performance-based agreements tie rebates and milestone payments to volume, contributing to an 18% year-over-year tender share increase and addressing roughly RMB 2.1bn of tender spend.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartners: 35+ international distributors, 12 local tender agents\u003c\/li\u003e\n\u003cli\u003eCoverage: ~1,200 hospitals\u003c\/li\u003e\n\u003cli\u003eImpact: 18% YoY tender share growth; ~RMB 2.1bn addressable tender spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic partnerships de-risk approvals, share R\u0026amp;D and scale global biologics commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHisun's partnerships—regulators, academia, biotech co-developers, CROs\/CMOs and distributors\/tender agents—de-risk approvals, share R\u0026amp;D costs and scale global commercialization. 2024 metrics: WHO PQ since 2001; biologics market $390B; CRO $56B; CMO $62B; 35+ distributors; 12 agents; ~1,200 hospitals; 18% YoY tender share; RMB 2.1bn tender spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulators\u003c\/td\u003e\n\u003ctd\u003eMarket access\/compliance\u003c\/td\u003e\n\u003ctd\u003eWHO PQ since 2001\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\/Hospitals\u003c\/td\u003e\n\u003ctd\u003eTrials\/RWE\u003c\/td\u003e\n\u003ctd\u003e35–45% investigator studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech\u003c\/td\u003e\n\u003ctd\u003eCo‑development\/licensing\u003c\/td\u003e\n\u003ctd\u003eBiologics market $390B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO\/CMO\u003c\/td\u003e\n\u003ctd\u003eTrial\/manufacturing scale\u003c\/td\u003e\n\u003ctd\u003eCRO $56B; CMO $62B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\/Agents\u003c\/td\u003e\n\u003ctd\u003eMarket entry\/tenders\u003c\/td\u003e\n\u003ctd\u003e35+ dist.; 12 agents; ~1,200 hospitals; RMB2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Hisun Pharmaceutical detailing customer segments, channels, value propositions, revenue streams and key resources across the 9 BMC blocks; includes competitive advantages, SWOT-linked insights and actionable recommendations for investors, partners and strategic planners.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Hisun Pharmaceutical’s business model with editable cells, allowing teams to quickly pinpoint value-chain pain points and streamline R\u0026amp;D, manufacturing, and distribution decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative \u0026amp; generic R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovative and generic R\u0026amp;D drives discovery, biosimilar development and formulation optimization across small and large molecules, concentrating on oncology, anti-infectives, cardiovascular and endocrine therapies. The pipeline mix targets biosimilars representing roughly 30% of programs and orphan\/oncology candidates prioritised for high unmet need. Leveraging analytics and QbD has reduced scale-up risk metrics by an estimated 30–40% and supported annual R\u0026amp;D spend near RMB 1.2 billion in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHisun Pharmaceutical (Shanghai Stock Exchange ticker 600267) manufactures APIs and finished dosages under cGMP, pursuing continuous process improvements to reduce batch variability and compliance risk. The company maintains bioreactors, fermentation suites and sterile fill\/finish lines for biologics and injectables to support commercial and contract production. A digital MES has been implemented to improve yield visibility and end-to-end traceability across production and supply chains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality \u0026amp; compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRun rigorous QC\/QA, validation, and data-integrity programs aligned to ICH and PIC\/S standards, embedding ICH E6\/E8 principles across manufacturing and R\u0026amp;D. Prepare for global inspections with documented audit trails and aim for CAPA closure targets ≤30 days to minimize supply risk. Maintain pharmacovigilance with ICH E2A 15-day serious AE reporting and regular product quality reviews tied to batch-release metrics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory \u0026amp; market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory \u0026amp; market access: Hisun files DMFs, ANDAs\/NDAs, MAAs and biosimilar dossiers across China, EU and US, manages post-approval variations, lifecycle strategies and labeling harmonization, and engages HTA and pricing bodies to secure reimbursement and formulary access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDMFs\/NDAs\/MAAs: multi-jurisdiction submissions\u003c\/li\u003e\n\u003cli\u003eLifecycle: variations \u0026amp; labeling alignment\u003c\/li\u003e\n\u003cli\u003eMarket access: HTA engagement for reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial \u0026amp; distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManage B2B sales to pharma clients, hospital tendering and international exports while delivering technical support and post-launch services to ensure product uptake and regulatory compliance. Optimize logistics, cold chain integrity and inventory turns to reduce lead times and minimize spoilage. Focus on channel relationships, contract management and service SLAs to sustain margins and accelerate market entry.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannel: B2B sales, hospital tenders, exports\u003c\/li\u003e\n\u003cli\u003eService: technical support, post-launch\u003c\/li\u003e\n\u003cli\u003eOps: cold chain, logistics, inventory turns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003eRMB 1.2bn\u003c\/strong\u003e R\u0026amp;D; \u003cstrong\u003e~30%\u003c\/strong\u003e biosimilars; oncology focus; QbD cuts scale-up risk \u003cstrong\u003e30-40%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHisun drives innovative and generic R\u0026amp;D (RMB 1.2bn R\u0026amp;D spend in 2024) with ~30% biosimilar programs and oncology\/orphan focus; QbD cut scale-up risk ~30–40%. Operates cGMP API, biologics and sterile fill\/finish lines with MES for traceability. QC\/QA aligned to ICH\/PIC\/S; CAPA ≤30 days and ICH E2A 15-day SAE reporting. Files DMFs\/NDAs\/MAAs across CN\/EU\/US and manages HTA engagement.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar share\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAPA target\u003c\/td\u003e\n\u003ctd\u003e≤30 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Hisun Pharmaceutical Business Model Canvas you’re previewing is the exact document you’ll receive after purchase, not a mockup or sample. When you complete your order, you’ll get the full, professionally formatted file—ready to edit, present, and apply. No hidden pages or altered content: what you see is what you’ll download and own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674945274233,"sku":"hisunpharm-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/hisunpharm-business-model-canvas.png?v=1755799351","url":"https:\/\/portersfiveforce.com\/products\/hisunpharm-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}